Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCS110 (Emactuzumab) in PVNS/GCTTS
NCT01643850Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2012
- Primary completion
- Dec 2017
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of emactuzumab in tenosynovial giant cell tumor (TGCT), sponsored by Novartis. Started Apr 2012; status: completed.
02
Drugs
emactuzumab
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT01643850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01643850.